Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.73 SEK | +1.36% | -1.06% | +38.66% |
03-13 | CombiGene's Epilepsy Project CG01 Receives Patent in Two New Countries | CI |
02-21 | Orphazyme A/S acquired an additional unknown minority stake in CombiGene AB (OM:COMBI). | CI |
Business Summary
Number of employees: 11
Sales per Business
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Novel Gene Therapies
100.0
%
| 84 | 100.0 % | 27 | 100.0 % | -68.23% |
Sales per region
SEK in Million | 2021 | Weight | 2022 | Weight | Delta |
---|---|---|---|---|---|
Sweden
100.0
%
| 84 | 100.0 % | 27 | 100.0 % | -68.23% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Peter Ekolind
CEO | Chief Executive Officer | 60 | 26/09/22 |
Louise Aspenberg
DFI | Director of Finance/CFO | 48 | 11/10/20 |
Daniela Morath
ADM | Chief Administrative Officer | 44 | 31/12/17 |
Karin Agerman
CTO | Chief Tech/Sci/R&D Officer | 51 | 31/12/17 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Gunilla Lundmark
BRD | Director/Board Member | 61 | 31/12/20 |
Director/Board Member | 59 | 31/12/19 | |
Director/Board Member | 54 | 30/09/14 | |
Per Lundin
BRD | Director/Board Member | 41 | - |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 19,801,197 | 11,880,966 ( 60.00 %) | 0 | 60.00 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
+38.66% | 6.84M | |
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |
- Stock Market
- Equities
- COMBI Stock
- Company CombiGene AB